DanielE.WeissMD

Journal Articles

• Evaluation of Pharmacokinetic and Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting  
  Daniel Weiss, Robert Knight, Simon Zhou, Maria Palmisano, and Nianhang Chen, Clinical Drug Investigation, 1/30/2015
• The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban  
  Karen S Brown, Prachi Wickremasingha, Dolly A. Parasrampuria, Daniel Weiss, Jarema Kochan, Victor Dishy, Ling He, and Minggao Shi, Thrombosis research, 1/1/2015
• Effects of CC-220, A CRL4 Cereblon E3 Ubiquitin Ligase Modulator, on Immune Responses  
  Ying Yi, Daniel Weiss, Peter Schafer, Mike Thomas, Allison Gaudy, Zhihong Yang, Liangang Liu, Edward O'Mara, and Maria Palmisano, Annals of the Rheumatic Diseases, 1/1/2015
• No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volun...  
  Nianhang Chen, Daniel Weiss, Jo Reyes, Liangang Liu, Claudia Kasserra, Xiaomin Wang, Simon Zhou, Gondi Kumar, Lilia Weiss, and Maria Palmisano, Cancer Chemotherapy and Pharmacolog, 1/1/2014
• Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects  
  Nobuko Matsushima, Frank Lee, Toshiyuki Sato, Daniel Weiss, and Jeanne Mendell, Clinical Pharmacology in Drug Development, 1/1/2013
• Absolute Bioavailability of Edoxaban in Healthy Subjects  
  Nobuko Matsushima, Frank Lee, Toshiyuki Sato, Daniel Weiss and Jeanne Mendell, American Association of Pharmaceutical Scientists 2011 Annual Meeting and Exposition, 1/23/2012
• Effects of Quinidine on Pharmacokinetics (PK) of Oral (PO) and Intravenously (IV) Administered Edoxaban  
  Nobuko Matsushima, J. Mendell, H. Zahir, F. Lee, T. Sato, J. Jin, and D. Weiss, American Society for Clinical Pharmacology and Therapeutics 113th Annual Meeting, 1/15/2012
• Play at Your Own Risk?  
  Weiss DE, Applied Clinical Trials, 1/1/2011
• Join now to see all

Abstracts/Posters

• Effects of CC-220, an oral immunomodulator, on immune responses.
  Ying Ye, Peter Schafer, Mike Thomas, Daniel Weiss, Allison Gaudy, Zeen Tong, Edward O'Mara, and Maria Palmisano, ASCPT 2015 Annual Meeting, 1/3/2015
• Evaluation of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple oral doses of CC-220 in healthy subjects.
  Mike Thomas, Ying Ye, Daniel Weiss, Allison Gaudy, Nianhang Chen, Zhihong Yang, Liangang Liu, Peter Schafer, Debbie Mandarino, Maria Palmisano, and Edward O'Mara, ASCPT 2015 Annual Meeting, 1/1/2015
• Population Pharmacokinetics and Exposure-Safety Of Lenalidomide In Patients With Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma.
  Nianhang Chen, Ene Ette, Simon Zhou, Daniel Weiss and Maria Palmisano, American Society of Hematology (ASH) 2013 Annual Meeting, New Orleans, LA, 1/1/2013
• Phase I Study of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine or Temsirolimus.
  Nianhang Chen, Daniel Weiss, Jo Reyes, Liangang Liu, Claudia Kasserra, Xaiomin Wang, Simon Zhou, Gondi Kumar, Lilia Weiss, and Maria Palmisano, ASH 2013 Annual Meeting, 1/1/2013
• A Randomized, Crossover, Phase 1 Study to Evaluate the Effect of a Strong CYP3A4 Inhibitor on Tivantinib (ARQ 197) Pharmacokinetics in Healthy Subjects.
  Hamim Zahir, Toshihiro Oguma, Daniel Weiss, Joseph Walker, and Taro Tokui, Annual Meeting of the American Association for Cancer Research, Chicago, IL, 1/31/2012
• Fluorescein Waglerin-1 detects early expression of the epsilon acetylcholine receptor
  McArdle JJ, Weiss DE, Meyenhofer MF, Stafford RG, and Schmidt JJ, Society for Neuroscience, 30th annual meeting, 1/4/2000
• Join now to see all

Other

• Study of the mouse epsilon-subunit nicotinic acetylcholine receptor development at the neuromuscular junction using a novel snake toxin, Waglerin-1. 
  Weiss DE